These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3862151)

  • 41. Prolactin and growth hormone response to levodopa in affective illness.
    Linkowski P; Brauman H; Mendlewicz J
    Neuropsychobiology; 1983; 9(2-3):108-12. PubMed ID: 6621850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An empirical comparison of three different borderline concepts.
    Kullgren G
    Acta Psychiatr Scand; 1987 Sep; 76(3):246-55. PubMed ID: 3673651
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Emotional and impulsive dimensions in bipolar disorder and borderline personality disorder].
    Leblanc A; Jarroir M; Vorspan F; Bellivier F; Leveillee S; Romo L
    Encephale; 2017 May; 43(3):199-204. PubMed ID: 27017320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biological markers in borderline personality disorders: an overview.
    Fleming JA
    Can J Psychiatry; 1988 Dec; 33(9):873. PubMed ID: 3214836
    [No Abstract]   [Full Text] [Related]  

  • 45. Identification of borderline personality disorder with the NIMH Diagnostic Interview Schedule.
    Swartz MS; Blazer DG; George LK; Winfield I; Zakris J; Dye E
    Am J Psychiatry; 1989 Feb; 146(2):200-5. PubMed ID: 2643363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Depression in borderline personality disorder: lifetime prevalence at interview and longitudinal course of symptoms.
    Perry JC
    Am J Psychiatry; 1985 Jan; 142(1):15-21. PubMed ID: 3871311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dexamethasone suppression test and Axis I diagnoses of inpatients with DSM-III borderline personality disorder.
    Baxter L; Edell W; Gerner R; Fairbanks L; Gwirtsman H
    J Clin Psychiatry; 1984 Apr; 45(4):150-3. PubMed ID: 6715286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comorbid bipolar disorder and borderline personality disorder and history of suicide attempts.
    Zimmerman M; Martinez J; Young D; Chelminski I; Morgan TA; Dalrymple K
    J Pers Disord; 2014 Jun; 28(3):358-64. PubMed ID: 24256102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The relationship between thought disorder and psychotic symptoms in borderline personality disorder.
    O'Connell M; Cooper S; Perry JC; Hoke L
    J Nerv Ment Dis; 1989 May; 177(5):273-8. PubMed ID: 2708971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder.
    Reich DB; Zanarini MC; Bieri KA
    Int Clin Psychopharmacol; 2009 Sep; 24(5):270-5. PubMed ID: 19636254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Borderline personality disorder: hypothalamus pituitary adrenal axis and findings from neuroimaging studies.
    Wingenfeld K; Spitzer C; Rullkötter N; Löwe B
    Psychoneuroendocrinology; 2010 Jan; 35(1):154-70. PubMed ID: 19837517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EEG in borderline personality disorder.
    Archer RP; Struve FA; Ball JD; Gordon RA
    Biol Psychiatry; 1988 Oct; 24(6):731-2. PubMed ID: 3167160
    [No Abstract]   [Full Text] [Related]  

  • 53. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
    Hollander E; Swann AC; Coccaro EF; Jiang P; Smith TB
    Am J Psychiatry; 2005 Mar; 162(3):621-4. PubMed ID: 15741486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Contributions of cortisol suppression tests to understanding of psychiatric disorders: a narrative review of literature].
    Tajima-Pozo K; Montes-Montero A; Güemes I; González-Vives S; Díaz-Marsá M; Carrasco JL
    Endocrinol Nutr; 2013; 60(7):396-403. PubMed ID: 23623464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder.
    Gardner DL; Cowdry RW
    Am J Psychiatry; 1986 Apr; 143(4):519-22. PubMed ID: 3513634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sensitization of the Neural Salience Network to Repeated Emotional Stimuli Following Initial Habituation in Patients With Borderline Personality Disorder.
    Denny BT; Fan J; Fels S; Galitzer H; Schiller D; Koenigsberg HW
    Am J Psychiatry; 2018 Jul; 175(7):657-664. PubMed ID: 29961363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discriminating borderline disorder from other personality disorders. Cluster analysis of the diagnostic interview for borderlines.
    Barrash J; Kroll J; Carey K; Sines L
    Arch Gen Psychiatry; 1983 Dec; 40(12):1297-302. PubMed ID: 6651464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuropsychological factors associated with borderline pathology in children.
    Paris J; Zelkowitz P; Guzder J; Joseph S; Feldman R
    J Am Acad Child Adolesc Psychiatry; 1999 Jun; 38(6):770-4. PubMed ID: 10361797
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Enhanced suppression of cortisol after dexamethasone in borderline personality disorder. A pilot study].
    Carrasco JL; Diaz-Marsá M; Ignacio Pastrana J; Molina R; Brotons L; Horcajadas C
    Actas Esp Psiquiatr; 2003; 31(3):138-41. PubMed ID: 12772042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Personality disorders in a nonclinical sample of adolescents].
    Chabrol H; Chouicha K; Montovany A; Callahan S; Duconge E; Sztulman H
    Encephale; 2002; 28(6 Pt 1):520-4. PubMed ID: 12506264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.